Literature DB >> 20378155

Osteoporosis and cardiovascular disease care in systemic lupus erythematosus according to new quality indicators.

Kristina L Demas1, Brendan T Keenan, Daniel H Solomon, Jinoos Yazdany, Karen H Costenbader.   

Abstract

OBJECTIVES: Quality indicators (QIs) for the assessment of care of patients with systemic lupus erythematosus (SLE) have been proposed. We evaluated care according to these proposed QIs for osteoporosis and cardiovascular disease (CVD) in patients with SLE in our rheumatology practice.
METHODS: We selected 200 patients with SLE according to American College of Rheumatology Criteria and ≥2 visits to our practice in 2007 to 2008. We performed a structured medical record review and collected demographics, SLE and past medical history, medications, laboratories and data concerning osteoporosis, and CVD management. We employed univariable analyses and multivariable regression analyses to test for factors associated with care meeting the proposed QIs.
RESULTS: Ninety-four percent of patients were female and 64% were white. Mean age was 46.3 years and mean lupus duration was 15.3 years. Twenty-nine percent were taking ≥7.5 mg prednisone per day for ≥3 months. The proportions of patients for whom care met the proposed QIs were as follows: 59% for bone mineral density testing, 62% for calcium and vitamin D supplementation, and 86% for antiresorptive or anabolic osteoporosis medications. Only 3% had 5 cardiac risk factors assessed within the year and 26% had 4 cardiac risk factors assessed annually. Smoking, fasting lipid panels, and diabetes mellitus were rarely assessed annually. Having a primary care physician within our health care network increased care meeting QIs.
CONCLUSIONS: Care according to newly proposed QIs for osteoporosis and CVD was suboptimal in our academic center. To standardize and improve care of patients with SLE, we suggest specific changes to the proposed QIs.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20378155      PMCID: PMC2932869          DOI: 10.1016/j.semarthrit.2010.01.001

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  27 in total

1.  Atherosclerosis and lupus: a work in progress.

Authors:  M D Lockshin; J E Salmon; M J Roman
Journal:  Arthritis Rheum       Date:  2001-10

2.  The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research.

Authors:  Oliver Sangha; Gerold Stucki; Matthew H Liang; Anne H Fossel; Jeffrey N Katz
Journal:  Arthritis Rheum       Date:  2003-04-15

3.  Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  J M Esdaile; M Abrahamowicz; T Grodzicky; Y Li; C Panaritis; R du Berger; R Côte; S A Grover; P R Fortin; A E Clarke; J L Senécal
Journal:  Arthritis Rheum       Date:  2001-10

Review 4.  How accelerated atherosclerosis in SLE has changed our management of the disorder.

Authors:  D S Hallegua; D J Wallace
Journal:  Lupus       Date:  2000       Impact factor: 2.911

Review 5.  Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.

Authors: 
Journal:  Arthritis Rheum       Date:  2001-07

6.  The bimodal mortality pattern of systemic lupus erythematosus.

Authors:  M B Urowitz; A A Bookman; B E Koehler; D A Gordon; H A Smythe; M A Ogryzlo
Journal:  Am J Med       Date:  1976-02       Impact factor: 4.965

Review 7.  The JUPITER trial: How will it change clinical practice?

Authors:  Karol E Watson
Journal:  Rev Cardiovasc Med       Date:  2009       Impact factor: 2.930

Review 8.  Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management.

Authors:  J E Salmon; M J Roman
Journal:  Curr Opin Rheumatol       Date:  2001-09       Impact factor: 5.006

9.  Risk factors for cardiovascular disease in systemic lupus erythematosus.

Authors:  E Svenungsson; K Jensen-Urstad; M Heimbürger; A Silveira; A Hamsten; U de Faire; J L Witztum; J Frostegård
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

10.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

View more
  15 in total

Review 1.  Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Authors:  Maureen McMahon; Bevra H Hahn; Brian J Skaggs
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

2.  Brief Report: Trends in Hospitalizations Due to Acute Coronary Syndromes and Stroke in Patients With Systemic Lupus Erythematosus, 1996 to 2012.

Authors:  Maria G Tektonidou; Zhong Wang; Michael M Ward
Journal:  Arthritis Rheumatol       Date:  2016-11       Impact factor: 10.995

3.  Healthcare quality in systemic lupus erythematosus: using Donabedian's conceptual framework to understand what we know.

Authors:  Erica F Lawson; Jinoos Yazdany
Journal:  Int J Clin Rheumtol       Date:  2012-02

4.  Rheumatologists' perception of systemic lupus erythematosus quality indicators: significant interest and perceived barriers.

Authors:  Carolyn Casey; Cecilia P Chung; Leslie J Crofford; April Barnado
Journal:  Clin Rheumatol       Date:  2016-11-22       Impact factor: 2.980

5.  Quality of care in systemic lupus erythematosus: the association between process and outcome measures in the Lupus Outcomes Study.

Authors:  Jinoos Yazdany; Laura Trupin; Gabriela Schmajuk; Patricia P Katz; Edward H Yelin
Journal:  BMJ Qual Saf       Date:  2014-03-10       Impact factor: 7.035

6.  Thirty-day hospital readmissions in systemic lupus erythematosus: predictors and hospital- and state-level variation.

Authors:  Jinoos Yazdany; Ben J Marafino; Mitzi L Dean; Naomi S Bardach; Reena Duseja; Michael M Ward; R Adams Dudley
Journal:  Arthritis Rheumatol       Date:  2014-10       Impact factor: 10.995

7.  Evaluation of quality indicators and disease damage in childhood-onset systemic lupus erythematosus patients.

Authors:  Julia G Harris; Kristyn I Maletta; Evelyn M Kuhn; Judyann C Olson
Journal:  Clin Rheumatol       Date:  2016-12-24       Impact factor: 2.980

Review 8.  Use of Quality Measures to Identify Disparities in Health Care for Systemic Lupus Erythematosus.

Authors:  Shilpa Arora; Jinoos Yazdany
Journal:  Rheum Dis Clin North Am       Date:  2020-09-09       Impact factor: 2.670

9.  Lipid Testing and Statin Prescriptions Among Medicaid Recipients With Systemic Lupus Erythematosus or Diabetes Mellitus and the General Medicaid Population.

Authors:  Sarah K Chen; Medha Barbhaiya; Michael A Fischer; Hongshu Guan; Tzu-Chieh Lin; Candace H Feldman; Brendan M Everett; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-01       Impact factor: 4.794

10.  Quality of care in systemic lupus erythematosus: application of quality measures to understand gaps in care.

Authors:  Jinoos Yazdany; Laura Trupin; Chris Tonner; R Adams Dudley; Joann Zell; Pantelis Panopalis; Gabriela Schmajuk; Laura Julian; Patricia Katz; Lindsey A Criswell; Edward Yelin
Journal:  J Gen Intern Med       Date:  2012-05-17       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.